The REVAKI-2 Trial tests the hypothesis that postoperative AKI will be reduced in cardiac surgery patients identified as being at increased risk of developing AKI preoperatively, following administration of sildenafil, a PDE-5 inhibitor. Here, PDE5A is linked to acute kidney injury.